HDT 321
Alternative Names: HDT-321Latest Information Update: 30 Sep 2025
At a glance
- Originator HDT Bio; University of Texas Medical Branch
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Crimean-Congo haemorrhagic fever virus infections
Most Recent Events
- 19 Sep 2025 National Institutes of Health's National Institute of Allergy and Infectious Diseases establishes CRADA with University of Texas Medical Branch for the development of HDT 321 in Crimean-Congo haemorrhagic fever virus infections
- 19 Sep 2025 The US FDA approves an IND application for HDT 321 in Crimean-Congo haemorrhagic fever virus infections
- 10 Jul 2025 Phase-I clinical trials in Crimean-Congo haemorrhagic fever virus infections (Prevention) in USA (IM) (NCT06799013)